Skip to main content

Market Overview

Trevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial

Trevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial
  • Trevena Inc's (NASDAQ: TRVN) TRV027 has been selected for an NIH ACTIV trial in COVID-19 patients that will be dosed in ~300 COVID-19 patients.
  • TRV027 combats disruption within the renin-angiotensin-aldosterone system (RAAS) by specifically binding to and rebalancing AT1 receptor activation, blocking the damaging pathway that leads to acute lung damage and abnormal blood clotting, while activating the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.
  • The trial, known as ACTIV-4d RAAS, evaluates treatments targeting the RAAS and determining whether modulation of the RAAS is an effective strategy for preventing progression to critical illness, multiorgan failure, or mortality in hospitalized COVID-19 patients.
  • Last month, TRV027 was included in an international Phase 2-Phase 3 trial in COVID-19 patients.
  • Price Action: TRVN shares are down 7.4% at $1.64 on the last check Thursday.

Related Articles (TRVN)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19 COVID-19 VaccineBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at